The U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense have agreed to supply about $486 million to drugmaker AstraZeneca PLC (NYSE: AZN) to develop the company’s AZD7442 COVID-19 treatment and vaccine. The funds will help support two trials of the company’s cocktail of drugs, both as a medicine to prevent infection and a pre-emptive treatment for patients who already have been infected with COVID-19.
AZD7442 is different from the company’s other drug, dubbed AZD1222, further trials of which were put on hold by the U.S. Food and Drug Administration (FDA). A U.K. participant in the late-stage clinical trial developed an unexplained illness after receiving a dose of AZD1222. In many countries, including the United Kingdom, clinical testing was allowed to resume. The United States is not among them.
AstraZeneca is about to commence a trial of the drug with 5,000 participants. Another 1,100 participants in a second trial will evaluate AZD7442’s efficacy as a post-exposure prophylaxis and pre-emptive treatment. The company plans additional trials of the drug with 4,000 participants to determine the cocktail’s value as a treatment for COVID-19.
The HHS and Defense Department funding also will pay for 100,000 doses in 2020 of the single-shot AZD7442 vaccine that is expected to provide protection against COVID-19 for up to 12 months. The two agencies provided more than $25 million earlier this year to develop and begin trials of AstraZeneca’s monoclonal antibody treatments. The U.S. government also will be able to acquire an additional 1 million doses of AZD7442 in 2021 under a separate agreement.
Last May, the U.S. government agreed to pay $1.2 billion for 300 million doses of AZD1222, but lacking an FDA emergency use authorization, none can be shipped. That’s just $4 per dose. The per-dose average for the AZD7442 cocktail is $4,860 for the first 100,000 doses. Presumably, this would decline if the drug is approved and the federal government exercises its option to acquire another 1 million doses.
CEO Pascal Soriot commented that the U.S. government investment in AZD7442 in a medicine that “has the potential to provide immediate and long-lasting effect in both preventing and treating COVID-19 infections” focuses on “helping the most vulnerable people.”
AstraZeneca’s share price was up about 0.8% Monday morning, at $55.15 in a 52-week range of $36.15 to $64.94. The U.K.-based firm’s price target is $59.10, and the company pays a dividend yield of 2.56%.
24/7 Wall St.Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
